ABC | Volume 114, Nº6, June 2020

Review Article Figueiredo Neto et al. Coronavirus and Myocardium Arq Bras Cardiol. 2020; 114(6):1051-1057 Sources of Funding There was no external funding source for this study. Study Association This study is not associated with any thesis or dissertation. 1. A referência correta é: Guan WJ, Liang WH, Zhao Y, et al. China Medical Treatment Expert Group for Covid-19. Comorbidity and its impact on 1590 patientswithCovid-1 9inChina:ANationwideAnalysis.EurRespirJ. 2020Mar 26; 2000547. doi: 10.1183/13993003.00547-2020 [Epub ahead of print]. 2. HoffmannM, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-80. 3. ZhaoY,ZhaoZ,WangY,ZhouY,MaY,ZuoW.Single-cellRNAexpressionprofiling ofACE2,theputativereceptorofWuhan2019-nCov.bioRxiv.2020Jan26. 4. Turner AJ, Hiscox JA, Hooper NM. ACE2: from vasopeptidase to SARS virus receptor. Trends Pharmacol Sci. 2004;25(6):291-4. 5. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al. Angiotensin- converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436(7047):112-6. 6. Costa IBSS, Bittar, CS, Rizk SI, Araújo Filho AE, Santos KAQ, Machado TIV, et al. The heart and COVID-19: what cardiologists need to know.. Arq Bras Cardiol. 2020 May 11. [Epub ahead of print]. 7. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020. [Published online 2020 March 25] doi: 10.1001/ jamacardio.2020 Mar 25. [Epub ahead of print]. 8. Guo T, Fan Y, Chen M. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020 Mar 27. [Epub ahead of print]. 9. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62. 10. Atri D, Siddidi HK, Lang J, Nauffal V, Morrow DA, Bohula EA. COVID-19 for the cardiologist: a current review of the virology, clinical epidemiology, cardiac and other clinical manifestations and potential therapeutic strategies. JACC Basic Transl Sci. 2020 Apr 10. [Epub ahead of print]. 11. Sarkisian L, Saaby L, Poulsen TS et al. Prognostic impact of myocardial injury related to various cardiac and noncardiac conditions. Am J Med. 2016;129(5):506-14.e1. 12. Libby P, Loscalzo J, Ridker P, Farkouh ME, Hsue PY, Fuster V, et al. Inflammation, immunity, and infection in atherothrombosis: JACC Review Topic of the Week. J Am Coll Cardiol. 2018;72(17):2071-81. 13. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, MorrowDA, et al. Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol. 2018;72(18):2231-64. 14. ChapmanAR,ShahASV,LeeKK,AnandA,FrancisO,AdamsonP,etal.Long-term outcomes in patients with type 2 myocardial infarction and myocardial injury. Circulation.2018;137(12):1236-45. 15. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost.2020;18(4):844-7. 16. Simmons J, Pittet JF. The coagulopathy of acute sepsis. Curr Opin Anaesthesiol. 2015;28(2):227-36. 17. Levi M, van der Poll T, Buller HR. Bidirectional relation between inflammation andcoagulation.Circulation.2004;109(22):2698-704. 18. Green J, Doughty L, Kaplan SS, Sasser H, Carcillo JA. The tissue factor and plasminogen activator inhibitor type-1 response in pediatric sepsis-induced multipleorgan failure.ThrombHaemost.2002;87(2):218-23. 19. Cox D, Kerrigan SW, Watson SP. Platelets and the innate immune system: mechanisms of bacterial-induced platelet activation. J Thromb Haemost. 2011;9(6):1097-107. 20. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020 Mar 12. [Epub ahead of print]. 21. Kumar A, Thota V, Dee L, Olson J, Uretz E, Parrillo JE. Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med. 1996;183(3):949-58. 22. Natanson C, Eichenholz PW, Danner RL, Eichacker PQ, Hoffman WD, Kuo GC, et al. Endotoxin and tumor necrosis factor challenges indogs simulate the cardiovascular profile of human septic shock. J Exp Med. 1989;169(3):823-32. 23. Pathan N, Hemingway CA, Alizadeh AA, Stephens AC, Boldrick JC, Oragui EE, et al. Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock. Lancet. 2004;363(9404):203-9. 24. Hobai IA, Edgecomb J, LaBarge K, Colucci WS. Dysregulation of intracellular calcium transportes in animal models of sepsis-induced cardiomyopathy. Shock. 2015;43(1):3-15. 25. Balligand JL, Ungureanu D, Kelly RA, Kobzik L, Pimental D, Michel T, et al. Abnormal contractile function due to induction ofnitric oxide synthesis in rat cardiac myocytes follows exposure to activated macrophage conditioned medium. J Clin Invest. 1993;91(5):2314-9. 26. Stanzani G, Duchen MR, Singer M. The role of mitochondria in sepsis-induced cardiomyopathy. Biochim Biophys Acta Mol Basis Dis. 2019;1865(4):759-73. 27. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall S, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-4. 28. Meyer P, Degrauwe S, Van Delden C, Ghadri JR, Templin C. Typical takotsubo syndrome triggered by SARS-CoV-2 infection. Eur Heart J. 2020;41(19):1860. 29. Sala S, Peretto G, Gramegna M, Palmisano A, Villatore A, Vignale D, et al. Acute myocarditis presenting as a reverse TakoTsubo syndrome in a patient with SARS-CoV-2 respiratory infection. Eur Heart J. 2020;41(19):1861-2. 30. Chazal HM, Del Buono MG, Keyser-Marcus L, Ma L, Moeller FG, Berrocal D, et al. Stress cardiomyopathy diagnosis and treatment: JACC state-of-the-art review. J Am Coll Cardiol. 2018;72(16):1955-71. 31. Bangalore S, Sharma A, Slotwiner A, Yatskar L, Harari R, Shah B, et al. ST-segment elevation in patients with Covid-19 — a case series. N Engl J Med. 2020 Apr 17. [Epub ahead of print]. 32. Corrales-Medina VF, Alvarez KN, Weissfeld LA, Angus DC, Chirinos JA, Chang CCH, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA. 2015;313(3):264-74. 33. Udell JA, Zawi R, Bhatt DL, Keshtkar-Jahromi M, Gaughran F, Phrommintikul A, et al. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA. 2013;310(16):1711-20. 34. Nguyen JL, Yang W, Ito K, Matte TD, Shaman J, Kinney PL. Seasonal influenza infections and cardiovascular disease mortality. JAMA Cardiol. 2016;1(3):274-81. References 1056